Ladirubicin

N/A

Report date: 2022/05/18 17:42:10
NME

Base Information

Drug NameLadirubicin
Drug Alias Name拉地比星FCE-28729PNU-159548
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A